At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
CF102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis
In Brief
A Phase 2 clinical trial evaluating CF102 and Placebo for Hepatocellular Carcinoma. Completed, enrolled 78 participants across 21 sites in 5 countries.
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesBulgaria, Israel, Romania, Serbia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartSep 2014
Primary CompletionNov 2017
Study CompletionDec 2021
TodayJul 2026
First PostedMay 1, 2014
Enrollment StartSep 1, 2014
Primary CompletionNov 27, 2017
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.2 years ago
Interventions
CF102drug
orally q12h
Placebodrug
orally q12 hours